Charles Schwab’s Exagen XGN Stock Holding History

Charles Schwab’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,074	Closed	-$218K	–	3653
2022 Q1	$218K	Hold	27,074	–	–	﹤0.01%	3291
2021 Q4	$315K	Hold	27,074	–	–	﹤0.01%	3275
2021 Q3	$369K	Hold	27,074	–	–	﹤0.01%	3219
2021 Q2	$406K	Buy	27,074 +16,821	+164%	+$258K	﹤0.01%	3203
2021 Q1	$180K	Hold	10,253	–	–	﹤0.01%	3329
2020 Q4	$136K	Hold	10,253	–	–	﹤0.01%	3296
2020 Q3	$112K	Hold	10,253	–	–	﹤0.01%	3244
2020 Q2	$128K	Buy	+10,253	New	+$139K	﹤0.01%	3227

Other funds holding XGN

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Charles Schwab's XGN Position: Q2 2022 in Review

Charles Schwab sold out of Exagen (XGN) in Q2 2022, closing a stake of 27,074 shares — an estimated $218K sold.

Charles Schwab first reported a position in XGN in Q2 2020 and held it in 8 quarters. The position peaked at $406K in Q2 2021. 47 funds tracked by Wall St. Rank hold XGN as of Q2 2022.

Charles Schwab reported no remaining Exagen position as of Q2 2022 after selling out during the quarter.
Charles Schwab sold 27,074 Exagen shares in Q2 2022, an estimated $218K.
Charles Schwab first reported a position in Exagen in Q2 2020 and held it in 8 quarters.
Charles Schwab's Exagen position peaked at $406K in Q2 2021.
47 funds tracked by Wall St. Rank held Exagen as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.